Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies ...

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable ...

Prostate cancer is one of the most frequently diagnosed cancers in men. Prostate tumor staging and disease aggressiveness are evaluated based on the Gleason scoring system, which is further used to ...

Explore how nanosensors are transforming cancer diagnostics by enabling earlier, more accurate, and less invasive detection ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Ark Surgical, a women's health-focused medical device innovator, has received FDA 510(k) clearance for LapBox® POWER, a ...

Tina Knowles, best known as Beyoncé and Solange’s mother, gets candid in her memoir, writing about being diagnosed with ...

Innovative genetic testing methods are reshaping reproductive health, offering early detection of genetic conditions and ...

MacroGenics, Inc.’s MGNX share price has surged by 12.70%, which has investors questioning if this is right time to sell.

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” ...